HUTCHMED News

HUTCHMED: HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Apr 26 20:30

HUTCHMED: Vesting of awards under the Long Term Incentive Plan

Apr 22 16:33

HUTCHMED: Audit Committee - Terms of Reference

Apr 17 16:37

HUTCHMED: Notification letter to non-registered shareholders and reply form: (1) Annual General Meeting ("AGM"); and (2) Notice of publication of the 2023 Annual Report, Circular, Notice of AGM and Form of Proxy in relation to the AGM and 2023 Sustainabili

Apr 8 16:36

HUTCHMED: Notification letter to registered holders and reply form: (1) Annual General Meeting ("AGM"); and (2) Notice of publication of the 2023 Annual Report, Circular, Notice of AGM and Form of Proxy in relation to the AGM and 2023 Sustainability Report

Apr 8 16:36

HUTCHMED: 2023 Annual Report and Notice of Annual General Meeting

Apr 8 16:35

HUTCHMED: Form of Proxy for Use at the Annual General Meeting

Apr 8 16:34

HUTCHMED: Notice of Annual General Meeting

Apr 8 16:33

HUTCHMED: Notice of Annual General Meeting; Proposals for Re-election of Directors and General Mandates to Issue New Shares and Repurchase Shares

Apr 8 16:33

HUTCHMED: 2023 Sustainability Report

Apr 8 16:31

HUTCHMED: 2023 Annual Report

Apr 8 16:30

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Apr 5 16:33

HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended March 31, 2024

Apr 2 16:19

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Apr 2 12:27

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Mar 28 08:00

HUTCHMED: Letters to non-registered shareholders and reply form: New Arrangements on Dissemination of Corporate Communications

Mar 22 17:29

HUTCHMED: Letters to registered shareholders and reply form: New Arrangements on Dissemination of Corporate Communications

Mar 22 17:26

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Mar 22 08:00

HUTCHMED: Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

Mar 14 17:04

HUTCHMED: Vesting of awards under the Long Term Incentive Plan

Mar 5 16:32